Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215799 · ClinicalTrials.gov registry record · Phase 2
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
A Phase 2 study, sponsored by CytRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01215799 is a Phase 2 study that has completed, run by CytRx. The registered enrollment target is 23 participants.
The verdict
NCT01215799, a Phase 2 study, has completed, sponsored by CytRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a Phase II open-label study evaluating the preliminary efficacy and safety of bafetinib administered as 240 mg orally twice daily in subjects with Hormone Refractory Prostate Cancer.
Interventions
- DRUG Bafetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215799
The ClinicalTrials.gov registry entry for NCT01215799 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytRx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bafetinib is the first listed.
NCT01215799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215799 about?
NCT01215799 is a clinical study titled "Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer". This is a Phase II open-label study evaluating the preliminary efficacy and safety of bafetinib administered as 240 mg orally twice daily in subjects with Hormone Refractory Prostate Cancer.
What is the current status of trial NCT01215799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2010-08. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01215799?
The interventions under investigation include: Bafetinib (DRUG).
Who is sponsoring clinical trial NCT01215799?
This trial is sponsored by CytRx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.